Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

378 results

• 1565GCCIndependent statistical analysis of Decitabine and Talazoparib in Untreated AML and R/R AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02878785).Phase 1/2Results postedn = 25NCT02878785
• 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 22NCT00117988
• 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00775268).Phase 1/2Results postedn = 31NCT00775268
• 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.: Complete Statistical AnalysisIndependent statistical analysis of 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2/3Results postedn = 146NCT00223977
• 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis: Complete Statistical AnalysisIndependent statistical analysis of 4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 72NCT01587898
• A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 136NCT00830037
• A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters: Complete Statistical AnalysisIndependent statistical analysis of A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 94NCT01196533
• A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN): Complete Statistical AnalysisIndependent statistical analysis of A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 134NCT00517530
• A First Human Study of a Ferroportin Antibody: Complete Statistical AnalysisIndependent statistical analysis of A First Human Study of a Ferroportin Antibody: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01330953).Phase 1Results postedn = 32NCT01330953
• A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP): Complete Statistical AnalysisIndependent statistical analysis of A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 9NCT02201290
• A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145): Complete Statistical AnalysisIndependent statistical analysis of A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 19NCT02711852
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 960NCT01309737
• A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 4NCT02697240
• A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate…Phase 1Results postedn = 35NCT02961881
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202): Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202): primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 60NCT02998476
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 26NCT01698801
• A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP): Complete Statistical AnalysisIndependent statistical analysis of A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 12NCT04669600
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial): primary endpoint results, effect…Phase 3Results postedn = 329NCT01100502
• A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic…Phase 3Results postedn = 1,101NCT01241591
• A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura): Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic…Phase 3Results postedn = 24NCT01433978
• A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 9NCT01440920
• A Phase I/II Trial of VR-CHOP in Lymphoma Patients: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II Trial of VR-CHOP in Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00634179).Phase 1/2Results postedn = 37NCT00634179
• A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 10NCT01563055
• A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma: primary…Phase 1/2Results postedn = 117NCT03677141
• A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 6NCT02042950
• A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib:…Phase 2Results postedn = 133NCT00777036
• A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 1NCT01378871
• A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 25NCT00384956
• A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 30NCT00858117
• A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 1NCT00479167
• A Phase II Trial of Regadenoson in Sickle Cell Anemia: Complete Statistical AnalysisIndependent statistical analysis of A Phase II Trial of Regadenoson in Sickle Cell Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01788631).Phase 2Results postedn = 100NCT01788631
• A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA): Complete Statistical AnalysisIndependent statistical analysis of A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 2,014NCT02694978
• A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase EARLY_1Results postedn = 2NCT02020837
• A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 40NCT00217594
• A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 23NCT01483690
• A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A: primary endpoint results,…Phase 4Results postedn = 45NCT04565236
• A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching: Complete Statistical AnalysisIndependent statistical analysis of A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01328262).Phase NAResults postedn = 12NCT01328262
• A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia: primary endpoint results, effect estimate…Phase 2Results postedn = 25NCT02665143
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 8NCT01279616
• A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]: Complete Statistical AnalysisIndependent statistical analysis of A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West…Phase NAResults postedn = 50NCT02377947
• A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin’s Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1Results postedn = 75NCT02875223
• A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia: Complete Statistical AnalysisIndependent statistical analysis of A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 504NCT01394991
• A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc – Von Willebrand Factor – XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A): Complete Statistical AnalysisIndependent statistical analysis of A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in…Phase 1/2Results postedn = 16NCT03205163
• A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib): Complete Statistical AnalysisIndependent statistical analysis of A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 662NCT01804140
• A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors: Complete Statistical AnalysisIndependent statistical analysis of A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 429NCT00186901
• A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE): Complete Statistical AnalysisIndependent statistical analysis of A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE): primary endpoint results, effect estimate with…Phase 2Results postedn = 80NCT01414205
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma: primary…Phase NAResults postedn = 114NCT02919670
• A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 72NCT02071225
• A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and…Phase 1Results postedn = 23NCT04313608
• A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody: Complete Statistical AnalysisIndependent statistical analysis of A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody: primary endpoint results, effect estimate with confidence…Phase 2/3Results postedn = 58NCT02069899

← All therapeutic areas